Nasus Pharma Ltd (NSRX) stock
Close on Nov 13, 2026Market cap $25.87MP/E –Yield –
Nasus Pharma Ltd reported revenue of $1.24B for fiscal 2025. Free cash flow was -$4.93M. At the latest close the market valued the company at $25.87M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $25.87M
- P/E ratio
- –
- Price to sales
- 0.02
- Price to book
- 2.35
- Dividend yield
- –
- Free cash flow yield
- -19.06%
Fundamentals
- Revenue
- $1.24B
- Net income
- -$5.86M
- EPS, diluted
- -$0.72
- Free cash flow
- -$4.93M
Trading
- Previous close
- $2.82
- Open
- $2.94
- Day's range
- $2.81 – $2.94
- Volume
- 4,679
- Average volume (20 days)
- 16,904
- 52-week range
- $1.98 – $9.50
- RSI (14 days)
- 38.5
- Volatility (1 year)
- 101.8%
- Relative volume
- 0.28×
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | NSRX | S&P 500 | Difference | NSRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -9.2% | -3.0% | −6.1 pts | ||
| 3 months | -10.3% | -2.8% | −7.5 pts | ||
| Year to date | -68.6% | +11.5% | −80.1 pts | ||
| 1 year | -63.7% | +13.5% | −77.1 pts |
Four years at a glance
Fiscal years 2022 to 2025, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Nasus Pharma filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Nasus Pharma
Pharmaceutical Preparations
Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company that develops powder-based intranasal medications for acute and emergency medical situations. The company utilizes proprietary technology to deliver uniform spherical powder formulations into the nasal cavity for rapid drug absorption. Its primary product candidate is NS002, an intranasal epinephrine powder spray designed to treat severe allergic reactions. It also develops NS001, an intranasal naloxone candidate for opioid overdose, alongside preclinical programs exploring intranasal treatments for seizures, organophosphate poisoning, and vomiting. Because its product candidates remain in clinical development without regulatory approval, the company currently has no commercial customers, targeting patients who require immediate emergency care.
Company profile, executives and historyNasus Pharma stock: common questions
What is Nasus Pharma's stock price?
NSRX closed at $2.87 on Nov 13, 2026, up 1.77% on the day. Over the past 52 weeks it traded between $1.98 and $9.50.
What is Nasus Pharma's market cap?
Nasus Pharma was worth $25.87M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is NSRX's P/E ratio?
Nasus Pharma lost money over fiscal 2025 (diluted EPS -$0.72), so it has no meaningful P/E ratio.
How much revenue does Nasus Pharma make?
Nasus Pharma reported revenue of $1.24B for fiscal 2025.
Does Nasus Pharma pay a dividend?
No. Nasus Pharma has not paid a cash dividend over the last twelve months.
How has NSRX stock performed over the past year?
Including dividends, NSRX returned -63.7% over the past year, against +13.5% for the S&P 500.
How many NSRX shares are sold short?
0M shares were sold short at the latest FINRA report, 1.93% of the float, or 3.6 days of average trading volume.
Who are Nasus Pharma's competitors?
Companies most similar to Nasus Pharma by business, industry and size include INSM, ACAD, KNSA, HRMY, IONS.
See a number that looks wrong?